Abstract
There are approximately 8,000 recognized rare diseases affecting close to 30 million people in the United States. Sponsors choosing to engage in research and development of drugs for rare diseases, known as orphan drugs, face challenges and opportunities that are unique to orphan drug development. Small population size, disease heterogeneity, and unknown natural histories, among other factors, must be considered when designing clinical trials for orphan drugs. Additionally, sponsors need to consider the quality and quantity of clinical trial information needed to support the approval of an orphan drug. To further understand these unique challenges, sponsors should partner with patient groups who can provide disease-specific perspectives and experiences, as well as conduct natural history studies, to better inform the design and evaluation of results from clinical trials. Novel technologies are changing the clinical trial landscape which provide sponsors a unique opportunity to employ novel, lifesaving technologies that can truly “cure” rare diseases. Incentives provided by the Orphan Drug Act and other FDA policies, such as market exclusivity, priority review vouchers, and tax credits, recognize the unique status of orphan drugs and serve to stimulate the development of these products.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Clinical Trials Transformation Initiative (2015) CTTI recommendations: effective engagement with patient groups around clinical trials, Oct 2015. https://www.ctti-clinicaltrials.org/sites/www.ctti-clinicaltrials.org/files/7-revised_pgct-recommendations-2019_final.pdf. Last visited 10 Mar 2020
Contesse M, Valentine J, Wall T, Leffler M (2019) The case for the use of patient and caregiver perception of change assessments in rare disease clinical trials: a methodologic overview. Adv Ther. https://doi.org/10.1007/s12325-019-00920-x
FDA (2014) Expedited programs for serious conditions – drugs and biologics, May 2014. https://www.fda.gov/media/86377/download
FDA (2016) Tropical disease priority review vouchers, Oct 2016. https://www.fda.gov/media/72569/download
FDA (2017) Pediatric rare diseases – a collaborative approach for drug development using Gaucher disease as a model, Dec 2017. https://www.fda.gov/media/109465/download
FDA (2018a) Clarification of orphan designation of drugs and biologics for pediatric subpopulations of common diseases, July 2018. https://www.fda.gov/media/109496/download
FDA (2018b) Patient-focused drug development: collecting comprehensive and representative input, June 2018. https://www.fda.gov/media/113653/download
FDA (2018c) Slowly progressive, low-prevalence rare diseases with substrate deposition that results from single enzyme defects: providing evidence of effectiveness for replacement or corrective therapies, July 2018. https://www.fda.gov/media/115408/download
FDA (2019a) Rare diseases: common issues in drug development, Jan 2019. https://www.fda.gov/media/119757/download
FDA (2019b) Rare diseases: natural history studies for drug development, Mar 2019. https://www.fda.gov/media/122425/download
FDA (2019c) Rare pediatric disease priority review vouchers, July 2019
FDA (2020) Human gene therapy for rare diseases, Jan 2020. https://www.fda.gov/media/113807/download
Mikami K (2017) Orphans in the market: the history of orphan drug policy. Soc Hist Med:1–22. https://doi.org/10.1093/shm/hkx098
National Institute of Health, National Center for Advancing Translational Sciences. (n.d.) FAQ about rare diseases. http://rarediseases.info.nih.gov/about-ordr/pages/31/frequently-asked-questions. Last visited 10 Mar 2020
Sasinowski F (2011) Quantum of effectiveness evidence in FDA’s approval of orphan drugs. Ther Innov Regul Sci. https://doi.org/10.1177/0092861511435906
Sasinowski F, Panico E, Valentine J (2015) Quantum of effectiveness evidence in FDA’s approval of orphan drugs: update, July 2010 to June 2014. Ther Innov Regul Sci. https://doi.org/10.1177/2168479015580383
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Valentine, J.E., Sasinowski, F.J. (2022). Orphan Drugs and Rare Diseases. In: Piantadosi, S., Meinert, C.L. (eds) Principles and Practice of Clinical Trials. Springer, Cham. https://doi.org/10.1007/978-3-319-52636-2_253
Download citation
DOI: https://doi.org/10.1007/978-3-319-52636-2_253
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52635-5
Online ISBN: 978-3-319-52636-2
eBook Packages: Mathematics and StatisticsReference Module Computer Science and Engineering